<DOC>
	<DOCNO>NCT01034540</DOCNO>
	<brief_summary>The objective study assess effect 4 g/d prescription omega-3 acid ethyl ester ( POM3 ) , compare placebo , index insulin sensitivity secretion , well aspects fast postprandial lipid lipoprotein profile , subject hypertriglyceridemia .</brief_summary>
	<brief_title>Effects Prescription Omega-3 Acids Glucose Lipoprotein Lipids Subjects With Hypertriglyceridemia</brief_title>
	<detailed_description>This trial utilize randomize , double-blind , two-period crossover design . At Visit 2 ( Week 0 ) , subject meet entry criterion randomize one two treatment sequence : placebo POM3 first 6 week phase follow study product receive first phase ( POM3 placebo ) second 6 week . There 2-week washout period treatment phase .</detailed_description>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<criteria>Men postmenopausal woman , age 1879 year . Fasting , triglyceride ( TG ) level borderline high high range . Fasting , low density lipoprotein cholesterol ( LDLC ) high range lipid alter therapy take stabledose statin therapy Provide write informed consent authorization protect health information Use lipidaltering medication , stop , except stable dose statin therapy . Use omega3 fatty acid ethyl ester medication dietary supplement &gt; 1.0 g/d eicosapentaenoic acid ( EPA ) , docosahexaenoic acid ( DHA ) , combination EPA DHA coronary heart disease ( CHD ) CHD risk equivalent Body mass index 45 kg per square meter Allergy sensitivity omega3 fatty acid , corn corn product ( e.g. , corn oil ) , Dalpha tocopherol ( vitamin E ) ingredient study drug Certain muscle , liver , kidney , lung gastrointestinal condition Poorly control hypertension Certain medication Active cancer treat within prior 2 year ( except nonmelanoma skin cancer )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>